PFIZER INC.
🇺🇸United States
- Country
- 🇺🇸United States
- Ownership
- Public
- Established
- 1849-01-01
- Employees
- 88K
- Market Cap
- $163.3B
- Website
- http://www.pfizer.com
Study Evaluating the Safety and Efficacy of Etanercept in Patients With Psoriatic Arthritis Treated by Dermatologists
Completed
- Conditions
- Arthritis, PsoriaticPsoriasisSkin Diseases, Papulosquamous
- Interventions
- First Posted Date
- 2006-02-17
- Last Posted Date
- 2014-02-26
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 129
- Registration Number
- NCT00293709
- Locations
- 🇩🇪
Pfizer Investigational Site, Muenchen, Germany
Study Evaluating the Safety and Efficacy of Etanercept in Patients With Psoriatic Arthritis Treated by Rheumatologists
Completed
- Conditions
- Arthritis, PsoriaticPsoriasisSkin Diseases, Papulosquamous
- Interventions
- First Posted Date
- 2006-02-17
- Last Posted Date
- 2014-02-26
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 1308
- Registration Number
- NCT00293722
- Locations
- 🇩🇪
Pfizer Investigational Site, Toerwang-Samerberg, Germany
Study Of SU011248 In Combination With Docetaxel In Patients With Metastatic Breast Cancer
- First Posted Date
- 2006-02-14
- Last Posted Date
- 2009-12-23
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 22
- Registration Number
- NCT00291577
- Locations
- 🇸🇪
Pfizer Investigational Site, Stockholm, Sweden
Voriconazole Versus Itraconazole In Primary Prophylaxis Of Invasive Fungal Infection (IFI) In Subjects With Allogeneic Hematopoietic Stem Cell Transplants (HSCT)
Phase 3
Completed
- Conditions
- Antifungal Prophylaxis of Invasive Fungal Infections
- Interventions
- First Posted Date
- 2006-02-10
- Last Posted Date
- 2015-11-20
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 489
- Registration Number
- NCT00289991
- Locations
- 🇬🇧
Pfizer Investigational Site, Manchester, United Kingdom
[S,S]-Reboxetine Dose-Range Finding Trial
Phase 2
Completed
- Conditions
- Pain
- First Posted Date
- 2006-02-08
- Last Posted Date
- 2011-06-08
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 280
- Registration Number
- NCT00288652
- Locations
- 🇺🇸
Pfizer Investigational Site, Tacoma, Washington, United States
A Study To Assess The Efficacy And Safety Of Voriconazole In Chinese Patients With Serious Deep Tissue Fungal Infections
Phase 4
Completed
- Conditions
- Invasive Fungal Infections
- First Posted Date
- 2006-02-07
- Last Posted Date
- 2008-06-12
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 77
- Registration Number
- NCT00288197
- Locations
- 🇨🇳
Pfizer Investigational Site, Tianjin, China
6-Month Safety And Efficacy Study Of TTP488 In Patients With Type 2 Diabetes And Persistent Albuminuria
Phase 2
Completed
- Conditions
- Diabetic Nephropathy
- Interventions
- Drug: PF-04494700 (TTP488)Other: Placebo
- First Posted Date
- 2006-02-06
- Last Posted Date
- 2009-10-01
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 110
- Registration Number
- NCT00287183
- Locations
- 🇨🇦
Pfizer Investigational Site, Saskatoon, Saskatchewan, Canada
A Clinical Trial Assessing the Impact of Inhaled Insulin on Glucose Disposition
Phase 3
Terminated
- Conditions
- Diabetes Mellitus
- First Posted Date
- 2006-02-06
- Last Posted Date
- 2008-02-21
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 22
- Registration Number
- NCT00287066
- Locations
- 🇺🇸
Pfizer Investigational Site, Pittsburgh, Pennsylvania, United States
Smoking Cessation in Subjects With Mild-to-moderate Chronic Obstructive Pulmonary Disease (COPD).
- First Posted Date
- 2006-02-01
- Last Posted Date
- 2010-04-20
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 504
- Registration Number
- NCT00285012
- Locations
- 🇪🇸
Pfizer Investigational Site, Madrid, Spain
A Three Day Trial of Azithromycin Plus Chloroquine for the Treatment of Uncomplicated Plasmodium Falciparum Malaria
- First Posted Date
- 2006-01-27
- Last Posted Date
- 2014-06-26
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 110
- Registration Number
- NCT00282919
- Locations
- 🇮🇳
Pfizer Investigational Site, Bambolim, Goa, India
© Copyright 2025. All Rights Reserved by MedPath